Valuation: AstraZeneca PLC

Market Cap 286B 255B 234B 213B 400B 27,062B 409B 2,797B 1,121B 14,323B 1,075B 1,052B 45,373B P/E 2026 *
24.3x
P/E 2027 * 20.7x
Enterprise Value 307B 274B 251B 228B 429B 29,031B 439B 3,000B 1,203B 15,365B 1,153B 1,128B 48,674B EV / Sales 2026 *
4.85x
EV / Sales 2027 * 4.45x
Free-Float
96.62%
Yield 2026 *
1.8%
Yield 2027 * 1.92%
1 day+1.98%
1 week+9.87%
Current month+0.46%
1 month+19.21%
3 months+19.45%
6 months+5.21%
Current year+1.70%
1 week 12,782
Extreme 12782
14,062
1 month 11,716
Extreme 11716
14,062
Current year 10,524
Extreme 10524
15,732
1 year 10,524
Extreme 10524
15,732
3 years 9,461
Extreme 9461
15,732
5 years 8,090.32
Extreme 8090.32
15,732
10 years 3,996
Extreme 3996
15,732
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Free

See remarks

2 0.0000% -
14/09/26 Free

Chief Financial Officer

73 0.0000%
14/09/26 Buy

Chairman

2,500 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%+9.87%+11.94%+36.47% 286B
+0.87%+10.55%+57.04%+139.28% 1,255B
+2.88%+1.13%+46.68%+80.68% 641B
+1.58%+1.89%+34.98%+106.37% 505B
+1.25%-0.73%+49.96%+66.94% 381B
+2.89%+5.53%+77.36%+42.54% 357B
+2.10%+3.90%+32.30%+59.38% 303B
+3.72%+6.10%+61.57%+75.70% 249B
+4.00%+9.74%+42.03%+115.31% 208B
+5.57%+11.84%-9.52%-59.32% 179B
Average +2.51%+3.06%+40.43%+66.34% 436.38B
Weighted average by Cap. +1.98%+3.91%+46.15%+87.45%

Financials

2026 *2027 *
Net sales 63.35B 56.45B 51.77B 47.05B 88.44B 5,987B 90.46B 619B 248B 3,169B 238B 233B 10,038B 67.38B 60.04B 55.06B 50.04B 94.07B 6,368B 96.22B 658B 264B 3,370B 253B 247B 10,676B
Net income 11.72B 10.45B 9.58B 8.71B 16.37B 1,108B 16.74B 114B 45.9B 586B 44B 43.06B 1,857B 13.59B 12.11B 11.11B 10.09B 18.98B 1,285B 19.41B 133B 53.22B 680B 51.02B 49.93B 2,154B
Net Debt 20.83B 18.56B 17.02B 15.47B 29.08B 1,969B 29.75B 203B 81.57B 1,042B 78.19B 76.52B 3,301B 13.46B 11.99B 11B 9.99B 18.79B 1,272B 19.22B 131B 52.69B 673B 50.51B 49.43B 2,132B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
04/11/26 GBX 14,024.00 +1.92% 2,469,065
03/11/26 GBX 13,760.00 -0.72% 2,536,689
02/11/26 GBX 13,860.00 -0.72% 2,992,033
30/10/26 GBX 13,960.00 +6.96% 4,486,055
29/10/26 GBX 13,052.00 +2.26% 1,421,354
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
184.62USD
Average target price
214.09USD
Spread / Average Target
+15.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC